Latest Manufacturing Processes News

NeuroScientific Biopharmaceuticals has initiated treatment of its fourth patient under the Special Access Scheme for StemSmart™, progressing towards a Phase 2 trial targeting severe Crohn’s disease.

Dotz Nano has successfully scaled up production of its proprietary CO₂ capture sorbents to kilogram volumes, setting the stage for commercial partnerships and cost efficiencies in the growing carbon capture market.

Metal Powder Works has secured a strategic partnership with Hardchrome Engineering, expecting USD 1-2 million in sales over the next year from innovative bronze alloy powders for laser cladding applications.

Avecho Biotechnology advances its pivotal Phase III CBD insomnia trial with 160 patients dosed and secures $2.5 million to accelerate manufacturing and regulatory efforts ahead of a 2026 interim analysis.

Nanoveu Limited has reported a major leap in drone endurance through its ultra-low-power AI chip technology, alongside advancing its next-generation 16 nm chip towards fabrication and expanding its U.S. sales network.

Dotz Nano has secured its first commercial order for its advanced carbon capture sorbent and raised A$1.2 million to accelerate development of its DotzEarth technology, marking a pivotal step towards commercialization in the growing DAC market.

NeuroScientific Biopharmaceuticals has secured regulatory approval for initial patient treatments under its Special Access Program for StemSmart™ in Crohn’s disease, alongside key executive appointments and a manufacturing partnership to support upcoming clinical trials.

Li-S Energy has marked a milestone with the production of Australia’s first lithium metal foils and expanded its footprint in the global defense sector, supported by new manufacturing capabilities and strategic partnerships.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for chronic wound treatment and advances regulatory filings for its TR Pro+® product, while gearing up for a major commercial rollout in early 2026.

Arovella Therapeutics has secured encouraging feedback from the US FDA on reagent testing for its CAR-iNKT cell therapy, setting the stage for an IND filing this quarter and clinical trials in early 2026.

Avecho Biotechnology has raised $2.5 million from institutional investors to fast-track manufacturing and regulatory preparations for its CBD TPM capsule amid ongoing Phase III trials.

Mesoblast Limited reports a 69% jump in net revenues from its pioneering cell therapy Ryoncil in Q1 FY2026, propelled by expanded physician adoption and new reimbursement pathways. The company also secures convertible note funding and plans pivotal adult trials.